

Année 2014

Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, Fabbro M, Lesoin A, Lortholary A, Pujade-Lauraine E.

**A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.**

*Annals of Oncology* - 2014 Nov; 25(11):2191-6. doi: 10.1093/annonc/mdu392

---

du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P.

**Incorporation of pazopanib in maintenance therapy of ovarian cancer.**

*Journal of Clinical Oncology* - 2014 Oct 20; 32(30):3374-82. doi: 10.1200/JCO.2014.55.7348.

---

Wilbaux M, Hénin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, Tod M, You B

**Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development.**

*Gynecologic Oncology* - 2014 Jun; 133(3):460-6. doi: 10.1016/j.ygyno.2014.04.003.

---

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I.

**Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.**

*Journal of Clinical Oncology* - 2014 May 1; 32(13):1302-8. doi: 10.1200/JCO.2013.51.4489

---

Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E.

**Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.**

*Journal of Clinical Oncology* - 2014 May 1; 32(13):1309-16. doi: 10.1200/JCO.2013.51.4240

---

# PUBLICATION DU GINECO

Pignata S, Scambia G, Katsaros D, Gallo C, **Pujade-Lauraine E**, De Placido S, Bologna A, **Weber B**, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); **Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO)**; Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIg) Investigators.

**Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.**

*The Lancet Oncology* - 2014 Apr; 15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X

---

Gonzalez-Martin A, **Gladieff L**, Tholander B, Stroyakovskiy D, Gore M, Scambia G, Oaknin A, Sneller V, Freuden sprung U, Pignata S; OCTAVIA Investigators.

**Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer).**

*Eur J Cancer*. 2014 Mar;50(4):862-3. doi: 10.1016/j.ejca.2013.12.001.

---

**Wilbaux M, Hénin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, Tod M, You B.**

**Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients.**

*British Journal of Cancer* - 2014 Mar 18; 110(6):1517-24. doi: 10.1038/bjc.2014.75

---

Vergote IB, Jimeno A, **Joly F**, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, **Lesoin A**, Casado A, Reinthaller A, Green J, Buck M, **Ray-Coquard I**, Ferrero A, **Favier L**, Reed NS, **Curé H**, **Pujade-Lauraine E**.

**Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.**

*Journal of Clinical Oncology* - 2014 Feb 1; 32(4):320-6. doi: 10.1200/JCO.2013.50.5669

---

**Maillet D, Goulvent T, Rimokh R, Vacher-Lavenu MC, Pautier P, Alexandre J, Pujade-Lauraine E, Devouassoux-Shisheboran M, Treilleux I, Ray-Coquard I, Savina A.**

**Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network.**

*Gynecologic Oncology* - 2014 Jan; 132(1):181-7. doi: 10.1016/j.ygyno.2013.10.013

Année 2014

Fujiwara H, Yokota H, Monk B, **Treilleux I**, **Devouassoux-Shisheboran M**, Davis A, Kim JW, Mahner S, Stany M, Pignata S, **Ray-Coquard I**, Fujiwara K.

**Gynecologic Cancer InterGroup (GCIg) consensus review for cervical adenocarcinoma.**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S96-101. doi: 10.1097/IGC.000000000000263*

---

Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, **Devouassoux-Shisheboran M**, Covens A, Lorusso D, Kurzeder C, Kim JW, **Gladieff L**, Bryce J, Friedlander M, Fujiwara K.

**Gynecologic Cancer InterGroup (GCIg) consensus review for clear cell carcinoma of the uterine corpus and cervix.**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S90-5. doi: 10.1097/IGC.000000000000297.*

---

Glasspool RM, González Martín A, Millan D, Lorusso D, Åvall-Lundqvist E, Hurteau JA, Davis A, Hilpert F, Kim JW, **Alexandre J**, Ledermann JA.

**Gynecologic Cancer InterGroup (GCIg) consensus review for squamous cell carcinoma of the ovary.**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S26-9. doi: 10.1097/IGC.000000000000209.*

---

Friedlander ML, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, **Selle F**, Small W, Witteveen E, Russell P.

**Gynecologic Cancer InterGroup (GCIg) consensus review for mullerian adenosarcoma of the female genital tract.**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S78-82. doi: 10.1097/IGC.000000000000239*

---

Pautier P, Nam EJ, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, **Ray-Coquard I**.

**Gynecologic Cancer InterGroup (GCIg) consensus review for high-grade undifferentiated sarcomas of the uterus.**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S73-7. doi: 10.1097/IGC.000000000000281.*

Amant F, **Floquet A**, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, **Ray-Coquard I**, Siddiqui N, Sykes P, Westermann AM, Seddon B

**Gynecologic Cancer InterGroup (GCIg) consensus review for endometrial stromal sarcoma.**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S67-72. doi: 10.1097/IGC.000000000000205.*

---

Hensley ML, Barrette BA, Baumann K, Gaffney D, Hamilton AL, Kim JW, Maenpaa JU, **Pautier P**, Siddiqui NA, Westermann AM, **Ray-Coquard I**

**Gynecologic Cancer InterGroup (GCIg) consensus review: uterine and ovarian leiomyosarcomas.**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S61-6. doi: 10.1097/IGC.000000000000261.*

---

Harter P, Gershenson D, **Lhomme C**, **Lecuru F**, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A.

**Gynecologic Cancer InterGroup (GCIg) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S5-8. doi: 10.1097/IGC.000000000000282*

---

Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, **Kurtz JE**, Glasspool RM, Small W Jr.

**Gynecologic Cancer InterGroup (GCIg) consensus review for uterine serous carcinoma.**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S83-9. doi: 10.1097/IGC.000000000000264.*

---

Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, **de la Motte Rouge T**, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ.

**Gynecologic Cancer InterGroup (GCIg) consensus review for ovarian germ cell tumors.**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S48-54. doi: 10.1097/IGC.000000000000223.*

---

**Ray-Coquard I**, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, **Rigaud DB**, Glasspool RM, Mezzanzanica D, Colombo N

**Gynecologic Cancer InterGroup (GCIg) consensus review for ovarian sex cord stromal tumors.**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S42-7. doi: 10.1097/IGC.000000000000249.*

Leitao MM Jr, Cheng X, Hamilton AL, Siddiqui NA, Jurgenliemk-Schulz I, Mahner S, Åvall-Lundqvist E, Kim K, **Freyer G**.

**Gynecologic Cancer InterGroup (GCIg) consensus review for vulvovaginal melanomas.**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S117-22. doi: 10.1097/IGC.000000000000198.*

---

Reed NS, Gomez-Garcia E, Gallardo-Rincon D, Barrette B, Baumann K, Friedlander M, Kichenadasse G, Kim JW, Lorusso D, Mirza MR, **Ray-Coquard I**.

**Gynecologic Cancer InterGroup (GCIg) consensus review for carcinoid tumors of the ovary.**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S35-41. doi: 10.1097/IGC.000000000000265.*

---

Satoh T, Takei Y, Treilleux I, **Devouassoux-Shisheboran M**, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileskin L, Åvall-Lundqvist E, **Pautier P**, Reed NS, Fujiwara K.

**Gynecologic Cancer InterGroup (GCIg) consensus review for small cell carcinoma of the cervix**

*Int J Gynecol Cancer. 2014 Nov; 24(9 Suppl 3):S102-8. doi: 10.1097/IGC.000000000000262.*